Table 4 The effect of alternative agent as first-line chemotherapy on treatment outcome of low-risk GTN
Variables* | Group A (n = 11) | Group B (n = 13) | P value |
|---|---|---|---|
Age (years) | 25 (21–49) | 29 (22–53) | 0.190 |
Gravidity | 3 (1–5) | 3 (1–7) | 0.700 |
Parity | 0 (0–2) | 1 (0–1) | 0.176 |
hCG before evacuation (IU/L) | 200,000 (1000–1,278,808) | 202,418 (20,000–998,083) | 0.620 |
Interval from HM to GTN (days) | 62 (14–153) | 100 (44–300) | 0.082 |
Largest dimension of tumor (cm) | 1.6 (0–7.3) | 0.6 (0–3.2) | 0.089 |
Number of metastases | 0 (0–2) | 0 (0–9) | 0.540 |
hCG before first-line chemotherapy (IU/L) | 129 (11–44,808) | 530 (13–15,885) | 0.794 |
FIGO stage | |||
I | 2 (18%) | 9 (69%) | 0.012 |
II | 0 (0%) | 0 (0%) | |
III | 9 (82%) | 4 (31%) | |
WHO risk score | 2 (0–4) | 1 (0–6) | 0.412 |
Resistant to first-line drug | 5 (45%) | 5 (38%) | 0.729 |
Resistant to single-agent drug | 1 (9%) | 3 (23%) | 0.596 |
Chemotherapy cycles to hCG normalization | 4.4 ± 1.7 | 2.8 ± 1.5 | 0.024 |
Total chemotherapy cycles | 6 (5–11) | 6 (3–9) | 0.261 |